Wardenafil – doêwiadczenie kliniczne
The clinical experience with vardenafil

Summary/Abstract: Vardenafil is an oral phosphodiesterase 5 (PDE-5) inhibitor with a very good pharmacodynamic and pharmacokinetic profile. It has the strongest affinity for its target enzyme in comparison to other PDE-5 inhibitors and it is also very selective towards PDE-5. The excellent efficacy of vardenafil in the treatment of erectile dysfunction has been shown in many clinical trials, including difficult-to-treat patients (with diabetes and after prostatectomy). High affinity for PDE-5 as well as quick absorption from the gastrointestinal tract may account for the very fast onset of action of vardenafil which in some patients occurs even 10-11 min after taking the drug. The results of the PROVEN study show that vardenafil markedly improves erectile function in patients with retrospectively established non-responsiveness to sildenafil. This suggests that pharmacologic differences between vardenafil and sildenafil may have clinical significance.

• Details
• Contents